Technology ID
E-044-1997-0

Immunotoxin with in-vivo T cell Suppressant Activity

Linked ID
TAB-1563
Inventors
David Neville (NIMH)
Huaizhong Hu (NIMH)
Jerry Thompson (NIMH)
Joshua Scharff (NIMH)
Judith Thomas (University of Alabama @ Birmingham)
Shenglin Ma (NIMH)
Stuart Knechtle (University of Wisconsin)
Lead Inventors
David Neville (NIMH)
Co-Inventors
Huaizhong Hu (NIMH)
Jerry Thompson (NIMH)
Joshua Scharff (NIMH)
Judith Thomas (University of Alabama @ Birmingham)
Shenglin Ma (NIMH)
Stuart Knechtle (University of Wisconsin)
ICs
NIMH
Commercial Applications
  • Treatment of autoimmune diseases such as multiple sclerosis, lupus, type I diabetes, aplastic anemia
  • Treatment of T cell leukemias and lymphomas such as cutaneous T cell leukemia/lymphoma (CTCL)
Competitive Advantages
  • Specificity of the immunotoxin avoids the killing of non-T cells, reducing side-effects associated with other mechanisms of treatment (e.g., radiation and cyclophosphamide) such as infection and induced malignancy.
  • A GMP production process has already been successfully implemented, and patient doses are available.
  • All testing required for an FDA issued IND has been completed, allowing faster evaluation of the efficacy of the invention.

Request More Info

Licensing Contact